Detalhe da pesquisa
1.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
N Engl J Med
; 390(15): 1359-1371, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38631003
2.
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
Oncologist
; 29(2): 142-150, 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589219
3.
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
N Engl J Med
; 385(8): 683-694, 2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407342
4.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(9): 1133-1144, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36055304
5.
Is there an intermediate-risk non-seminoma? long-term treatment results from a single center.
J BUON
; 19(3): 775-9, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25261666
6.
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 8(4): 546-552, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35142815
7.
Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors.
In Vivo
; 35(5): 2981-2990, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34410998